IGC Pharma Inc Stock Price, News & Analysis

IGC Pharma (NYSE American:IGC) has reported positive interim results from its Phase 2 clinical trial of IGC-AD1, targeting agitation in Alzheimer's patients. The trial demonstrated significant reductions in sleep disturbances: 71% reduction at week 2 (p=.012) and 78% reduction at week 6 (p=.02) compared to placebo, measured via NPI-12 Sleep Subscale.

IGC-AD1, a cannabinoid-based partial CB1 receptor agonist, shows promise in addressing sleep disorders affecting up to 44% of Alzheimer's patients. The treatment's mechanism differs from traditional sedatives, potentially offering a safer alternative to current options like Trazodone and Suvorexant, which have shown effectiveness in dementia patients.

The ongoing CALMA trial's complete analysis is expected by end-2025. The company plans to evaluate IGC-AD1 as an Alzheimer's disease-modifying drug, targeting a global sleep aid market projected to exceed $100 billion by 2030.

IGC Pharma (NYSE American:IGC) has announced the expansion of its Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. The trial expansion aims to accelerate patient enrollment and broaden the company's clinical footprint in developing treatments for Alzheimer's-related agitation.

The CALMA trial at HHS will be led by Dr. Alexandra Papaioannou, Executive Director of HHS' Geras Centre for Aging Research. HHS, one of Canada's leading academic and research hospitals, brings significant expertise in geriatric care and dementia research to the study. The collaboration focuses on developing therapies to address agitation in Alzheimer's patients, a significant challenge affecting patients, families, and caregivers.

IGC Pharma (NYSE American:IGC) has expanded its Phase 2 CALMA trial for IGC-AD1, adding BayCare's St. Anthony's Hospital in St. Petersburg, Florida as a new trial site. IGC-AD1 is a combination therapy targeting agitation in Alzheimer's dementia, which affects up to 76% of patients.

The trial will be led by Dr. Michael A. Franklin, a board-certified neurologist at St. Anthony's Hospital. The ongoing 146-patient Phase 2 trial has shown promising interim results, including significant reductions in agitation and exploratory cognitive improvements, with no serious adverse events reported.

IGC-AD1's dual-API formulation interacts with CB1 and CB2 receptors and targets neuroinflammation. Preclinical studies demonstrated a 20% reduction in amyloid plaques and 50% improvement in spatial memory. The expansion into Florida aims to improve diversity in trial recruitment through the state's diverse population.

IGC Pharma (NYSE American: IGC) announced on March 12, 2025, that Ascendiant Capital Markets has released a coverage report following IGC's Q3 results. The report suggests potential positive clinical data in 2025 could serve as strong catalysts for the stock. Notably, Ascendiant has raised their price target to $4.25.

The company clarified that analyst reports represent the views of those analysts exclusively and not necessarily those of IGC Pharma. IGC emphasized it is not responsible for the content, accuracy, or timelines provided by analysts.

IGC Pharma (NYSE American:IGC) announced that Alliance Global Partners (AGP) has released an analyst update research report titled 'Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results.' The company explicitly states that analyst views represent those analysts only and not necessarily IGC Pharma's views. IGC emphasizes it is not responsible for the content, accuracy, or timelines provided by analysts, and referencing these analysts or distributing their opinions does not imply IGC's endorsement of the information, conclusions, or recommendations.

IGC Pharma has announced the development of a new AI-driven diagnostic model for improved detection of Alzheimer's disease and other forms of dementia. The model aims to address current diagnostic challenges that often rely on invasive procedures and subjective assessments.

The AI platform integrates clinical datasets from leading research databases including NACC, ADNI, and PPMI. It analyzes multiple data points such as neuroimaging biomarkers, cognitive assessments, genetic risk factors, and medical history using transformer-based neural networks to deliver personalized diagnostic insights.

With dementia affecting over 55 million people worldwide and Alzheimer's accounting for 60-80% of cases, this initiative represents part of IGC Pharma's broader AI strategy in neurodegenerative disease research. The company aims to reduce misdiagnosis rates and enable earlier, more accurate treatment interventions.

IGC Pharma (NYSE American:IGC) is expanding its Holiby™ wellness brand with two new product lines: Longevity and Renew, targeting the anti-aging market. The company is implementing a multi-channel commercial strategy through e-commerce, white-label partnerships, and digital marketing.

The new products include Longevity Gummies for cognitive and cellular health support, featuring NAD+ boosting compounds, Lion's Mane Mushroom, and antioxidants, and Renew Gummies for energy and resilience, containing NAD+ metabolism support, Chaga Mushroom, and plant-based adaptogens.

This expansion complements IGC Pharma's clinical-stage drug development, including its Phase 2 trial (CALMA) of IGC-AD1 for Alzheimer's. The company is targeting the global longevity and anti-aging market, projected to exceed $182 billion by 2028, focusing on consumers aged 40+ seeking health-conscious solutions.

IGC Pharma reported its Q3 FY2025 financial results, highlighting progress in its Phase 2 CALMA trial for IGC-AD1, aimed at reducing agitation in Alzheimer's patients. The company generated $257,000 in revenue, a 26% increase from the same period last year, driven by white-label sales of over-the-counter formulations.

Key financial metrics show SG&A expenses decreased by 49% to $1.0 million, while R&D expenses decreased by 6% to $852,000. The net loss was $1.8 million ($0.02 per share), compared to $5.8 million ($0.08 per share) in the previous year. The company plans to expand IGC-AD1's application as an Alzheimer's disease-modifying therapy targeting brain plaques and tangles.

Notable achievements include winning two PREPARE Challenge awards and enrolling patients at Baycrest Academy in Toronto for the CALMA trial. The company also reported positive interim data showing cognitive benefits in Alzheimer's patients.

IGC Pharma has announced the launch of Holiby™, a wellness brand entering the $75 billion wellness market. The company will manufacture immunity and energy gummies at its Washington State facilities, creating a new revenue stream while continuing its pharmaceutical research on Alzheimer's disease and metabolic disorders.

The initial product line includes Immunity Gummies containing Elderberry, Echinacea, and Reishi Mushrooms, and Energy Gummies featuring Ashwagandha, Ginseng, and Maca Root. Products will be sold through direct-to-consumer channels and white-label partnerships.

The company aims to target health-conscious consumers aged 25 to 55+, particularly women (60-70%), through digital marketing, e-commerce, and social media influencer strategies.